Literature DB >> 21109227

Dominant mutations in KBTBD13, a member of the BTB/Kelch family, cause nemaline myopathy with cores.

Nyamkhishig Sambuughin1, Kyle S Yau, Montse Olivé, Rachael M Duff, Munkhuu Bayarsaikhan, Shajia Lu, Laura Gonzalez-Mera, Padma Sivadorai, Kristen J Nowak, Gianina Ravenscroft, Frank L Mastaglia, Kathryn N North, Biljana Ilkovski, Hannie Kremer, Martin Lammens, Baziel G M van Engelen, Vicki Fabian, Phillipa Lamont, Mark R Davis, Nigel G Laing, Lev G Goldfarb.   

Abstract

We identified a member of the BTB/Kelch protein family that is mutated in nemaline myopathy type 6 (NEM6), an autosomal-dominant neuromuscular disorder characterized by the presence of nemaline rods and core lesions in the skeletal myofibers. Analysis of affected families allowed narrowing of the candidate region on chromosome 15q22.31, and mutation screening led to the identification of a previously uncharacterized gene, KBTBD13, coding for a hypothetical protein and containing missense mutations that perfectly cosegregate with nemaline myopathy in the studied families. KBTBD13 contains a BTB/POZ domain and five Kelch repeats and is expressed primarily in skeletal and cardiac muscle. The identified disease-associated mutations, C.742C>A (p.Arg248Ser), c.1170G>C (p.Lys390Asn), and c.1222C>T (p.Arg408Cys), located in conserved domains of Kelch repeats, are predicted to disrupt the molecule's beta-propeller blades. Previously identified BTB/POZ/Kelch-domain-containing proteins have been implicated in a broad variety of biological processes, including cytoskeleton modulation, regulation of gene transcription, ubiquitination, and myofibril assembly. The functional role of KBTBD13 in skeletal muscle and the pathogenesis of NEM6 are subjects for further studies.
Copyright © 2010 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109227      PMCID: PMC2997379          DOI: 10.1016/j.ajhg.2010.10.020

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  25 in total

Review 1.  Clinical and genetic heterogeneity in nemaline myopathy--a disease of skeletal muscle thin filaments.

Authors:  D Sanoudou; A H Beggs
Journal:  Trends Mol Med       Date:  2001-08       Impact factor: 11.951

Review 2.  Nemaline myopathy: current concepts. The ENMC International Consortium and Nemaline Myopathy.

Authors:  K N North; N G Laing; C Wallgren-Pettersson
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

Review 3.  Nemaline myopathy: a clinical study of 143 cases.

Authors:  M M Ryan; C Schnell; C D Strickland; L K Shield; G Morgan; S T Iannaccone; N G Laing; A H Beggs; K N North
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

4.  A mutation in the alpha tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy.

Authors:  N G Laing; S D Wilton; P A Akkari; S Dorosz; K Boundy; C Kneebone; P Blumbergs; S White; H Watkins; D R Love
Journal:  Nat Genet       Date:  1995-01       Impact factor: 38.330

Review 5.  Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family.

Authors:  Lionel Pintard; Andrew Willems; Matthias Peter
Journal:  EMBO J       Date:  2004-04-08       Impact factor: 11.598

6.  Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere.

Authors:  L Thierfelder; H Watkins; C MacRae; R Lamas; W McKenna; H P Vosberg; J G Seidman; C E Seidman
Journal:  Cell       Date:  1994-06-03       Impact factor: 41.582

7.  A locus on chromosome 15q for a dominantly inherited nemaline myopathy with core-like lesions.

Authors:  I M P Gommans; M Davis; K Saar; M Lammens; F Mastaglia; P Lamont; G van Duijnhoven; H J ter Laak; A Reis; O J M Vogels; N Laing; B G M van Engelen; H Kremer
Journal:  Brain       Date:  2003-06-04       Impact factor: 13.501

8.  Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases.

Authors:  Manabu Furukawa; Yizhou Joseph He; Christoph Borchers; Yue Xiong
Journal:  Nat Cell Biol       Date:  2003-10-05       Impact factor: 28.824

9.  Sequence and structural analysis of BTB domain proteins.

Authors:  Peter J Stogios; Gregory S Downs; Jimmy J S Jauhal; Sukhjeen K Nandra; Gilbert G Privé
Journal:  Genome Biol       Date:  2005-09-15       Impact factor: 13.583

10.  Molecular phylogeny of the kelch-repeat superfamily reveals an expansion of BTB/kelch proteins in animals.

Authors:  Soren Prag; Josephine C Adams
Journal:  BMC Bioinformatics       Date:  2003-09-17       Impact factor: 3.169

View more
  60 in total

1.  Clinical utility gene card for: nemaline myopathy.

Authors:  Kristen J Nowak; Mark R Davis; Carina Wallgren-Pettersson; Phillipa J Lamont; Nigel G Laing
Journal:  Eur J Hum Genet       Date:  2012-04-18       Impact factor: 4.246

2.  An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia.

Authors:  Cristina Dias; Murat Sincan; Praveen F Cherukuri; Rosemarie Rupps; Yan Huang; Hannah Briemberg; Kathryn Selby; James C Mullikin; Thomas C Markello; David R Adams; William A Gahl; Cornelius F Boerkoel
Journal:  Hum Mutat       Date:  2012-02-28       Impact factor: 4.878

3.  Cullin-3-RING ubiquitin ligase activity is required for striated muscle function in mice.

Authors:  James B Papizan; Alexander H Vidal; Svetlana Bezprozvannaya; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Biol Chem       Date:  2018-04-13       Impact factor: 5.157

4.  New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients.

Authors:  Daniela Piga; Francesca Magri; Dario Ronchi; Stefania Corti; Denise Cassandrini; Eugenio Mercuri; Giorgio Tasca; Enrico Bertini; Fabiana Fattori; Antonio Toscano; Sonia Messina; Isabella Moroni; Marina Mora; Maurizio Moggio; Irene Colombo; Teresa Giugliano; Marika Pane; Chiara Fiorillo; Adele D'Amico; Claudio Bruno; Vincenzo Nigro; Nereo Bresolin; Giacomo Pietro Comi
Journal:  J Mol Neurosci       Date:  2016-04-22       Impact factor: 3.444

5.  Clinical utility gene card for: Nemaline myopathy - update 2015.

Authors:  Kristen J Nowak; Mark R Davis; Carina Wallgren-Pettersson; Phillipa J Lamont; Nigel G Laing
Journal:  Eur J Hum Genet       Date:  2015-02-25       Impact factor: 4.246

6.  Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease.

Authors:  Justin L Chen; Kelly L Walton; Adam Hagg; Timothy D Colgan; Katharine Johnson; Hongwei Qian; Paul Gregorevic; Craig A Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-12       Impact factor: 11.205

7.  The kelch protein KLHDC8B guards against mitotic errors, centrosomal amplification, and chromosomal instability.

Authors:  Maxwell M Krem; Ping Luo; Brandon I Ing; Marshall S Horwitz
Journal:  J Biol Chem       Date:  2012-09-17       Impact factor: 5.157

8.  Expanding the phenotype associated with the NEFL mutation: neuromuscular disease in a family with overlapping myopathic and neurogenic findings.

Authors:  Pankaj B Agrawal; Mugdha Joshi; Nicholas S Marinakis; Klaus Schmitz-Abe; Pedro D S C Ciarlini; Jane C Sargent; Kyriacos Markianos; Umberto De Girolami; David A Chad; Alan H Beggs
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

9.  Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy.

Authors:  Coen A C Ottenheijm; Danielle Buck; Josine M de Winter; Claudia Ferrara; Nicoletta Piroddi; Chiara Tesi; Jeffrey R Jasper; Fady I Malik; Hui Meng; Ger J M Stienen; Alan H Beggs; Siegfried Labeit; Corrado Poggesi; Michael W Lawlor; Henk Granzier
Journal:  Brain       Date:  2013-05-28       Impact factor: 13.501

10.  KLHL40 deficiency destabilizes thin filament proteins and promotes nemaline myopathy.

Authors:  Ankit Garg; Jason O'Rourke; Chengzu Long; Jonathan Doering; Gianina Ravenscroft; Svetlana Bezprozvannaya; Benjamin R Nelson; Nadine Beetz; Lin Li; She Chen; Nigel G Laing; Robert W Grange; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.